Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123962
Published online Nov 15, 2026. doi: 10.4251/wjgo.123962
Published online Nov 15, 2026. doi: 10.4251/wjgo.123962
Table 1 Baseline characteristics of interferon and nucleos(t)ide analogs groups before and after propensity score matching, n (%)
| Character | Before PSM | After PSM | ||||||
| IFN group | NAs group | P value | SMD | IFN group | NAs group | P value | SMD | |
| Sex | - | - | 0.56 | - | - | - | 0.219 | - |
| Female | 29 (24.17) | 67 (27.02) | -0.067 | 15 (21.13) | 42 (28.97) | - | -0.175 | |
| Male | 91 (75.83) | 181 (72.98) | 0.067 | 56 (78.87) | 103 (71.03) | - | 0.175 | |
| Age | - | - | 0.359 | - | - | - | 0.68 | - |
| Male < 40 years or female < 50 years | 45 (37.50) | 81 (32.66) | - | 0.1 | 29 (40.85) | 55 (37.93) | - | 0.083 |
| Male ≥ 40 years or female ≥ 50 years | 75 (62.50) | 167 (67.34) | - | -0.1 | 42 (59.15) | 90 (62.07) | - | -0.083 |
| Family history of HCC | - | - | 0.005 | - | - | - | 0.622 | - |
| No | 103 (85.83) | 180 (72.58) | 0.38 | 56 (78.87) | 110 (75.86) | - | 0.058 | |
| Yes | 17 (14.17) | 68 (27.42) | -0.38 | 15 (21.13) | 35 (24.14) | - | -0.058 | |
| Liver cirrhosis | < 0.001 | - | - | - | 0.267 | - | ||
| Non-cirrhosis | 80 (66.67) | 103 (41.53) | - | 0.533 | 39 (54.93) | 68 (46.90) | - | 0.164 |
| Compensatory cirrhosis | 40 (33.33) | 145 (58.47) | - | -0.533 | 32 (45.07) | 77 (53.10) | - | -0.164 |
| Alpha-fetoprotein ≥ 7.0 ng/mL | - | - | < 0.001 | - | - | - | 0.288 | - |
| No | 101 (84.17) | 127 (51.21) | 0.903 | 53 (74.65) | 98 (67.59) | - | 0.144 | |
| Yes | 19 (15.83) | 121 (48.79) | -0.903 | 18 (25.35) | 47 (32.41) | - | -0.144 | |
| Liver nodules detected on imaging | - | - | 0.939 | - | - | - | 0.536 | - |
| No | 89 (74.17) | 183 (73.79) | - | 0.009 | 57 (80.28) | 111 (76.55) | - | 0.118 |
| Yes | 31 (25.83) | 65 (26.21) | - | -0.009 | 14 (19.72) | 34 (23.45) | - | -0.118 |
| Diabetes | - | - | 0.012 | - | - | - | 1 | - |
| No | 115 (95.83) | 217 (87.50) | - | 0.417 | 66 (92.96) | 136 (93.79) | - | -0.04 |
| Yes | 5 (4.17) | 31 (12.50) | - | -0.417 | 5 (7.04) | 9 (6.21) | - | 0.04 |
| Alcohol intake | - | - | 0.304 | - | - | - | 0.536 | - |
| No | 94 (78.33) | 182 (73.39) | 0.12 | 57 (80.28) | 111 (76.55) | - | 0.118 | |
| Yes | 26 (21.67) | 66 (26.61) | -0.12 | 14 (19.72) | 34 (23.45) | - | -0.118 | |
| Fatty liver | - | - | 0.823 | - | - | - | 0.633 | - |
| No | 105 (87.50) | 219 (88.31) | - | -0.024 | 60 (84.51) | 126 (86.90) | - | -0.078 |
| Yes | 15 (12.50) | 29 (11.69) | - | 0.024 | 11 (15.49) | 19 (13.10) | - | 0.078 |
| Platelet count (× 109/L) | 174 | 134.5 | < 0.001 | 0.826 | 163 | 149 | 0.103 | 0.252 |
| (146.00, 209.25) | (89.00, 177.25) | (139.00, 197.50) | (108.00, 190.00) | |||||
| HBsAg (IU/mL) | 378.49 | 1440.72 | < 0.001 | -1.043 | 495.81 | 818.42 | 0.088 | -0.262 |
| (87.61, 1013.48) | (559.95, 3118.72) | (157.23, 1409.65) | (425.93, 2236.81) | |||||
| HBeAg | - | - | < 0.001 | - | - | - | 0.245 | - |
| Negative | 100 (83.33) | 133 (53.63) | 0.797 | 53 (74.65) | 97 (66.90) | - | 0.16 | |
| Positive | 20 (16.67) | 115 (46.37) | -0.797 | 18 (25.35) | 48 (33.10) | - | -0.16 | |
| HBV DNA (lg IU/mL) | 0.00 (0.00, 2.01) | 2.90 (0.00, 5.30) | < 0.001 | -1.045 | 0.00 (0.00, 2.43) | 1.86 (0.00, 3.69) | 0.081 | -0.236 |
- Citation: Hao M, Liu CR, Zhang M, Zhou XQ, Jiang ZC, Gao XH, Zhang X, Wang WJ, Wang YK, Jia XL, Li YP, Dang SS. Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123962
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123962.htm
- DOI: https://dx.doi.org/10.4251/wjgo.123962